GREEN & AGRI-BIOTECH
Green & Agri-Biotech is where biotechnology, agri-food value chains and the environment begin to speak the same language. At Technoscience, we treat it as an operational platform: bioprocesses to improve agri-food yield and sustainability, environmental biotech for bioremediation and intelligent monitoring, new skills to turn data, plants and environmental metrics into defensible industrial decisions. This section explains how we support companies, consortia and territories in moving from “green” as a slogan to “green” as physical accounting and measurable outcomes.
A hub connecting agri-food value chains, the environment and industry
In this section you will find three pathways that make the area concrete GREEN & AGRI-BIOTECHNOLOGY. These are not awareness-raising articles, but working maps designed for those who must make decisions about processes, plants, environmental metrics and internal capabilities.
Bioprocesses and Sustainability: Agri-Food Biotechnology Applications puts agri-food bioprocesses at the centre: fermentation, enzymatic bioconversions, waste valorisation, bio-based coatings and energy layouts assessed through LCA, water footprint and carbon footprint. It shows how to design stable, scalable processes in which sustainability and margins reinforce rather than exclude one another.
Environmental Biotechnology: Bioremediation and Monitoring explains how to use microbial consortia, plants, enzymes and environmental biosensors for in situ/ex situ bioremediation and continuous monitoring governed by a data platform: sensors, sampling, predictive models and reports that bring together science, regulation and social acceptability.
New Skills for Agri-Food Biotechnology is dedicated to teams: hybrid profiles spanning process bioengineering, data science/bioinformatics, quality by design, LCA and supply chain. It explains which roles an agri-biotech company genuinely needs, which KPIs they must move (yield, stability, off-spec, energy/product, CO₂/functional unit) and how to build career paths without wasting time on ornamental roles.
If you work in agri-food value chains, the environment, plants or ESG strategies, each of these pathways is designed to give you operational criteria, not labels, and to show you how Technoscience can contribute to the project from pilot stage to industrial scale.
How to work with us: what is really needed at the outset
To assess a project in the GREEN & AGRI-BIOTECHNOLOGY we ask for a number of concrete elements. First: the operational objective, whether an agri-food bioprocess, a bioremediation intervention or capability-building across the value chain, expressed as a clear, non-generic question. Second: the state of theplant and data – raw materials, biocatalysts, process layout, available measurements, and any LCAs or environmental indicators already calculated. Third: contextual constraints, from regulatory and food-safety requirements to requests from customers, large-scale retailers or local areas. In return, we offer a technical-industrial fit check that brings biology, process, data and sustainability into a coherent sequence, and a realistic TRL pathway proposal, integrating bioprocesses, data platforms and the capabilities needed to move the project from pilot to industrial scale.
Choose Technoscience!
If you are designing an agri-food bioprocess, an environmental biotech intervention or want to strengthen the capabilities of your value chain, use this form to request an initial fit check. In a short call, we align objectives, plant status, available data, environmental metrics and regulatory or market constraints. Once the basic elements are clear, we jointly define a pathway with milestones, KPIs and priorities (yield, stability, off-spec, energy/product, CO₂/functional unit) that makes the project measurable and scalable. If critical gaps emerge, we make them explicit immediately, so you can decide whether to close them or redesign the ambition without wasting time and resources.
Frequently Asked Questions
The questions you ask us most often
It is an approach that defines the the actual biology of the disease (tissues, markers and omics profiles where indicated) and links it to diagnostic and therapeutic decisions diagnostic and therapeutic personalised. It does not stop at generic classifications or guidelines applied wholesale: it builds a individual pathway measurable through robust clinical endpoints.
We start from risk classification and by the clinical scope of use. Requirements, risk management, clinical evaluation, software validation where present, and a plan for post-market surveillance. Documentation accompanies the entire lifecycle; compliance is not an event, it is a process.
It means speaking the standard languages of the sector (e.g. HL7/FHIR), maintain stable mappings, guarantee import/export without lock-in, and allow clinicians to see the data within its context (EHR, LIS, PACS) without duplication or manual copying.
Data-driven platforms collect, normalise and interpret medical data from certified devices, turning raw signals into clinically useful information for prevention, diagnosis and continuous monitoring.
Certified medical devices such as portable ECGs, pulse oximeters, multisensor wearables and environmental sensors underpin reliable remote monitoring and proactive prevention, both in healthcare and in the workplace.
Informed consent specific and understandable, compliant data governance, measures for pseudonymisation/de-identification, safety plans and audit documented, controls on the pre-analytical and analytical phases, and a return-of-results plan of results where required. If the project leads to clinical decisions or regulated products, additional requirements apply (clinical evaluations, MDR, GCP), and must be integrated from the outset.
An enabling role. The biobanks ensure traceable and comparable samples; the omics broaden the understanding of the underlying mechanisms (inflammatory, metabolic and genetic). When integrated with rigorous protocols and real-world data, make reproducible the evidence and accelerate translation towards clinical trials or clinical adoption.
With privacy by design and security by design: data minimisation, encryption in transit and at rest, access control, environment segmentation, audit trails and incident-response procedures. Roles and legal bases are made explicit; suppliers are also assessed for business continuity.
Integrated platforms enable intelligent surveillance, anticipating clinical events through composite indices and predictive algorithms and facilitating timely, personalised interventions instead of fixed-interval checks.
The data collected undergo normalisation, quality verification and audit-trail processes; they are managed according to security and privacy protocols compliant with applicable regulations (such as the GDPR).
With a reasoned request that describes purposes, study design, ethical criteria and sample/data requirements. The competent committee assesses consistency, proportionality and impact. Access, when granted, is conditional with quality protocols, traceability of use and the return of outcomes needed to update the biobank’s knowledge base.